Recent VIRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2025 10:00:32 PM
- Viracta Therapeutics Announces Wind Down of Operations • GlobeNewswire Inc. • 02/05/2025 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2025 09:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2025 10:14:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2025 09:08:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:39:52 PM
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives • GlobeNewswire Inc. • 12/26/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2024 10:14:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2024 09:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 10:20:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2024 12:30:08 PM
- Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 09:46:38 PM
- Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma • GlobeNewswire Inc. • 11/06/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 10:10:04 PM
- Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:25 AM
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2024 11:05:00 AM
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan • GlobeNewswire Inc. • 08/14/2024 11:00:00 AM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM
ECGI Holdings Invests in AI-Powered Fantasy Sports Startup Payday Fantasy • ECGI • Jun 10, 2025 8:30 AM
Avant Technologies Signs Letter of Intent for a Business Combination • AVAI • Jun 10, 2025 8:00 AM
NEXT10, Inc. Announces Acquisition of Torreon Group, Inc. • NXTN • Jun 9, 2025 8:42 AM
Maybacks Global Entertainment, LLC and Plex Sign Global Licensing and Distribution Agreement • AHRO • Jun 6, 2025 8:30 AM
Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership • BLOZF • Jun 5, 2025 8:54 AM